Phenobarbital (PB), a non-genotoxic hepatocarcinogen in rodents, has been studied extensively but its mechanism of carcinogenic action is unclear. PB appears to function as a tumor promoter by selectively inducing the growth of preneoplastic hepatocytes. In the present study, the comparative effects of PB at tumor-promoting and non-promoting doses were examined in male B6C3F1 mice and male F344 rats. In addition, the mechanism by which PB produced the selective induction of preneoplastic cell growth (increased DNA synthesis/cell proliferation and/or decreased apoptosis) was investigated. Preneoplastic focal lesions were produced using diethylnitrosamine (DEN). After the lesions were histologically apparent, mice and rats were fed PB (10, 100, or 500 mg/kg NIH-07 diet) or control diet and sampled after 7, 30 and 60 days of treatment In both mice and rats, 100 and 500 mg PB/kg increased the number and the relative volume of focal lesions. In rats and mice, 10 mg PB/kg did not enhance focal lesion growth. The preneoplastic lesions that clonaUy expanded due to phenobarbital treatment were predominantly eosinophilic in appearance. In addition, DNA synthesis in focal hepatocytes was significantly increased in the 100 and 500 mg PB/kg diet In PB-treated mice and rats, there also was a significant decrease in the rates of apoptosis in focal hepatocytes. Therefore, our data showed that PB at doses of 100 and 500 mg/kg diet promoted focal hepatic lesion growth both by increasing DNA synthesis and cell proliferation and by decreasing the rate of apoptosis.
Introduction
Hepatocarcinogenic chemicals can be separated into two broad mechanistic classes, genotoxic and non-genotoxic (epigenetic) (1) . Hepatic carcinogenesis is a multistep process currently defined by at least three stages: initiation, promotion and progression (1) (2) (3) . It has been proposed that non-genotoxic carcinogens exert their effects at the tumor promotion stage (3) (4) (5) . Phenobarbital (PB*) is an example of a non-genotoxic hepatocarcinogen. PB does not appear to be mutagenic based on short-term mutagenicity studies, yet PB chronically fed to mice and rats results in hepatic cancer (6) (7) (8) (9) (10) . PB had a doseresponse effect on the increase in hepatic cancer, and at lower doses appeared to exhibit a threshold (11) (12) (13) . Diethylnitrosamine (DEN) treatment (80 mg/kg body wt gavage) followed by 70 weeks of PB dietary feeding in Sprague-Dawley rats did not increase the incidence of hepatocellular cancer at doses of 62.5 and 125 mg/kg diet but did lead to significant increases in hepatic tumor incidence at PB concentrations of 250, 500 and 1000 mg/kg diet (11) . PB concentrations of 75 mg/ml and lower did not increase the number or volume of hepatic preneoplastic focal lesions in F344 rats initiated with DEN (13) . F344 rats initiated with 10 mg DEN/kg and receiving partial hepatectomy followed by 7-8 months of PB treatment exhibited a significant increase in the number of preneoplastic lesions at PB doses >50 mg/kg. In this same study, a noeffect level for PB promotion of hepatic focal lesions was found to be 10 mg/kg (11) . These studies suggested that a threshold existed for PB to function as a tumor promoter. In the mouse, much less is known about the dose-response ability of PB to promote preneoplastic lesion growth. A dose of 500 mg PB/kg diet following DEN treatment in adult mice has been shown to increase both the number and the volume of preneoplastic lesions (14) .
Although the exact mechanism by which PB functions as a tumor promoter has not been elucidated, the clonal expansion of initiated cells into preneoplastic focal lesions appears to be the salient effect (4, 15) . This increased growth of preneoplastic lesions may be attributed to increased DNA synthesis and cell proliferation and/or decreased apoptosis (15) (16) (17) (18) (19) (20) (21) . PB, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), cyproterone acetate, and a-hexachlorocylohexane have been shown to increase focal hepatocyte DNA synthesis in the rat, leading to selective growth of preneoplastic lesions (15, 17) . PB and nafenopin have also been reported to inhibit apoptosis in rat hepatic focal lesions and produce lesion growth without increasing DNA synthesis (18) (19) (20) . TCDD, in contrast, has been shown to produce both an inhibitory effect on focal apoptosis as well as increasing focal DNA synthesis (17, 21) . These studies in rat liver suggest that hepatocytes in preneoplastic focal lesions can be 'promoted' by modulating apoptosis and/or DNA synthesis depending on the chemical agent involved.
Phenotypic diversity in preneoplastic lesions may impart differences in the potential of these lesions to progress to neoplasia (22) . PB treatment in DEN-initiated rats has been shown previously to increase selectively both the number and volume of eosinophilic preneoplastic lesions (23, 24) . In addition, PB treatment in DEN-initiated mice has been shown to increase significantly the number of eosinophilic focal lesions and hepatocellular adenomas (14, 25) . Although eosinophilic lesions have been shown to increase in size and number after PB treatment (23, 24) , alterations in apoptosis and DNA synthesis in phenotypically distinct hepatic lesions have not been clearly investigated in either the F344 rat or the B6C3F1 mouse.
Accumulating evidence indicates that PB selectively enhances the growth of preneoplastic lesions in mice and rats (4, 15) ; however, little is known about the dose dependence of mis effect. Furthermore, most studies to date investigating the effect of PB upon hepatic lesion DNA synthesis/proliferation and apoptosis have been limited to the rat (15) (16) (17) (18) (19) (20) (21) . The presented study examined the effect of carcinogenic and noncarcinogenic PB doses on the selective growth of DEN-induced preneoplastic hepatic lesions in F344 rats and B6C3F1 mice and correlated the changes in DNA synthesis and apoptosis in phenotypically distinct focal lesions. Where previous studies have suggested that there is a role for both DNA synthesis and apoptosis in the tumor promotion process in the rat (15) (16) (17) (18) (19) (20) (21) , these processes have not been defined in the mouse.
Materials and methods
Chemicals DEN and PB (99% pure) were purchased from Sigma Chemical Co. (St Louis, MO). N1H-07 diets containing 0.0 (control), 10, 100 and 500 mg PB/kg diet were formulated by Dyets (Bethlehem, PA).
Animals
Three week old male Fisher 344 rats and male B6C3F1 mice were purchased from Harlan Sprague-Dawley Co. (Indianapolis, IN). Animals were housed in polycarbonate cages with filter tops in an AAALAC-certified animal facility. All animals were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All animals received N1H-07 diet in pelletized form and deionized water ad libitum. All animals were acclimated for 1 week prior to treatment with DEN.
Experimental design
Male Fisher 344 rats were given two i.p. injections of 150 mg DEN/kg body wt after the acclimation period to produce hepatic focal lesions and neoplasms (15) . When focal lesions were apparent (after 4 months), the rats were randomly placed into the following treatment groups (five rats per group): 10 mg PB/kg diet, 100 mg PB/kg diet, 500 mg PB/kg diet or control diet. Adult B6C3F1 mice were given two i.p. injections per week of 25 mg DEN/ kg body wt for 8 weeks. When focal lesions were apparent (after 5 months), the mice were randomly placed into one of the above dose groups (five mice per group). All rats and mice were killed at 7, 30 and 60 days after continuous dietary treatment. Osmotic mini-pumps [bromodeoxyuridine (BrdU), 16 mg/ ml of PBS] purchased from Alzet Co. [model 2ML1 (rats) and 2001 (mice), Palo Alto, CA], were surgically implanted into five animals from each dose group 7 days prior to killing the animals. At sampling, animals were humanely killed by ether asphyxiation, weighed and necropsied. The livers were removed in toto, weighed and examined for the presence of grossly visible lesions. The livers were then separated by lobe and sectioned into 1-2 mm strips. Strips of liver from each lobe were fixed in formalin for 48-72 h and then embedded into paraffin. A total of three paraffin blocks per animal were produced. Serial sections for each block were sectioned and stained with H&E or with anti-BrdU immunohistochemically (see below). Preneoplastic lesions were identified by previously described classifications (26) .
Stereotogy
The volume and frequency of altered hepatic foci and neoplastic lesions were quantitated by stereologic methods (27) . Briefly, total liver areas and hepatocellular lesions were traced using a projection scope or a drawing tube on a microscope respectively. The liver and lesion areas were calculated using Sigma Scan/Image software (Jandel Scientific, Corte Madre, CA) on an IBM computer.
BrdU immunohistochemical staining and quantification
BrdU immunohistochemistry was performed according to previously published methods with minor modifications (28) . Hepatocytes that had incorporated BrdU were easily visualized by the accumulation of red pigment within the nuclei as compared to the counterstained blue nuclei of unlabeled cells. A stretch of duodenum for each animal was included on all slides to ensure proper staining and incorporation of BrdU into the tissues. In focal lesions, all hepatocytes were scored. Labeling index (the percentage of cells in Sphase) was determined by dividing the number of hepatocytes with BrdUlabeled nuclei by the total number of hepatocytes counted.
Apoptosis H&E-stained slides were used to quantitate the incidence of apoptosis. Apoptosis in the liver was defined and quantitated as previously described (29, 30) . In addition, the morphological presence of apoptosis, presented in this study from H&E-stained slides, was validated using two unique methodologies [Apoptag Staining Kit, Oncor Inc., Gaithersburg, MD, and a fluorescent microscopy method (21) ]. The number of apoptotic focal hepato-cytes and the total number of focal hepatocytes were counted in H&E-stained sections. The number of apoptotic focal hepatocytes in the lesion was divided by the total number of hepatocytes in that section of lesion and multiplied by 100 to achieve an apoptotic index. At least 1500 focal hepatocytes were scored from all foci, and, whenever possible, 500 focal hepatocyte from each phenotypic lesion class were scored per dose group.
Statistics
Statistical difference (P < 0.05) from control values for all data was determined by using ANOVA followed by a Dunnett's post hoc test (31) .
Results
The effect of PB treatment on body weight and relative liver weight (liver wt/body wt ratio) in F344 rats is shown in Table  I . Treatment of 500 mg PB/kg diet resulted in an increased relative liver weight after 7, 30 and 60 days of exposure. Rats treated with 100 mg PB/kg diet had increased relative liver weights after 30 and 60 days (Table I ). In Table II , the effect of PB treatment on body weight and relative liver weight in B6C3F1 mice is shown. Treatment with 100 and 500 mg PB/ kg diet resulted in an increased relative liver weight after 7 and 30 days of exposure. After 60 days of PB treatment, there were no significant increases in relative liver weight in any dose group. No significant increases in the body weight over control was observed for mice or rats treated with PB at any dose or at any sampling time examined (Tables I and II) .
The effect of PB on the number of hepatic focal lesions in rats is shown in Table HI . Following treatment with 100 and 500 mg PB/kg diet, an increase in the number of hepatic focal lesions was seen from DEN-only control values after 7, 30 (at the 500 mg PB/kg dose only) and 60 days of exposure. This increase appeared to be involved predominantly in eosinophilic focal lesions (Table El) . Table FV shows the effect of PB on hepatic focal lesion volume in F344 rats. PB at concentrations of 100 and 500 mg/ kg diet produced an increase in the hepatic focal lesion volume after 7, 30 and 60 days of treatment. As with the focal lesion number (Table El) , the volume increase was restricted to the eosinophilic lesions.
An increase in the total focal DNA synthetic rate in F344 rats treated for 7, 30 and 60 days with the highest dose of PB studied (500 mg/kg diet) was seen (Table V) . Both basophilic and eosinophilic hepatic lesions in rats fed 500 mg PB/kg diet exhibited significant increases in DNA synthesis at all three sampling times examined. In addition, a significant increase in eosinophilic lesion DNA synthesis was observed in rats fed 100 mg PB/kg diet (7 and 60 days) and in clear cell focal lesions at 500 mg PB/kg diet (30 days).
The rate of apoptosis in F344 rat lesions was inversely related to the dietary PB concentration (Table VI) . A decrease in apoptosis was seen in the total focal lesions after exposure to 500 mg PB/kg diet after 7, 30 and 60 days. A decrease in apoptosis was also observed following treatment with 100 mg PB/kg diet in focal lesions after 7 days of treatment. The apoptotic rate was also decreased in eosinophilic appearing focal lesions after 7 days exposure to either 100 or 500 mg/ kg diet.
In mice (Table VIT) , PB produced an increase in the number of hepatic focal lesion after 7, 30 and 60 days. After 7 days of treatment, an increase in the number of focal lesion was seen at the 500 mg PB/kg diet dose. After 30 days of exposure to PB, the two highest doses studied (100 and 500 mg PB/kg diet) produced an increase in the hepatic focal lesions compared to DEN-only control. Following 60 days of treatment Values represent the mean ± SD of the body weight (g) and the relative liver weight (liver to body weight ratio) in five F344 rats per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. (V < 0.05). Values represent the mean ± SD of the number of preneoplastic focal lesions per liver in five F344 rats per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. (°P < 0.05). (Table VII) , all doses of PB examined (10, 100 and 500 mg PB/kg diet) displayed a significant increase (2-to 3-fold) in the number of focal lesions compared to the DEN-only group. This increase in the total number of focal lesions was also seen in eosinophilic appearing focal lesions when the foci were morphologically characterized by phenotype. In eosinophilic mouse liver lesions (Table VTT) , a PB dose of 500 mg/kg diet produced a significant increase in the number of focal lesions per liver after 7, 30 and 60 days of treatment. After 60 days of treatment, an increase in the number of eosinophilic focal lesions was also seen in the group fed the 100 mg PB/kg diet group. Hepatic focal lesion volume was also examined in B6C3F1 mice (Table VIII) . PB at 100 and 500 mg/kg diet produced a significant increase in the volume of hepatic focal lesion percentage after 30 and 60 days of treatment. Once again, eosinophilic lesions appeared to show the greatest response to PB, displaying an increase in the focal lesion volume at all three time points examined. The labeling index of hepatic focal lesions was examined in mice following treatment with PB (Table IX) . In mice fed 500 mg PB/kg diet, a significant increase in the labeling index of focal lesions was observed after 7, 30 and 60 days of treatment. When focal lesions were subsequently categorized by morphological phenotypes, basophilic, eosinophilic and clear cell focal lesions all showed a significant increase in labeling index following treatment with 500 mg PB/kg diet The apoptotic rate in mouse Values represent the mean ± SD of the focal lesion percentage volume in five F344 rats per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. (V < 0.05). Values represent the mean ± SD of the hepatic focal lesion BrdU labeling index (%) in five F344 rats per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. ("/> < 0.05). Values represent the mean ± SD for hepatic lesion rates of apoptosis in five F344 rats per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test (*P < 0.05). Values represent the mean ± SD of the preneoplastic focal lesion number per liver in five B6C3F1 mice per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. ("/> < 0.05). Values represent the mean ± SD of the focal lesion percentage volume in five B6C3F1 mice per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test ("/> < 0.05). Values represent the mean ± SD of the focal lesion BrdU labeling index (%) in five B6C3F1 mice per group treated with PB (0, 10, 100 and 500 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Statistical significance from the DEN-only group was determined by ANOVA followed by a Dunnett's post hoc test. (V < 0.05). ND (not determined) indicates that there were an insufficient number of focal lesions available for evaluation of BrdU labeling index. hepatic foci also showed a decrease following PB treatment (Table X) . In focal lesions in mice treated with 500 mg PB/ kg diet, there was a significant decrease in the rate of apoptosis after 7 and 60 days of treatment. In addition, a decrease in the rate of apoptosis was observed in eosinophilic focal lesions at a dose of 500 mg PB/kg diet after 30 and 60 days of treatment.
Discussion
From the data presented above, it is apparent that PB increased the lesion number, volume and DNA synthesis, and decreased apoptosis in DEN-induced hepatic focal lesions in both mice and rats. Changes in these endpoints have been attributed to tumor promotion (2), strongly suggesting that PB functions at the stage of tumor promotion in the hepatocarcinogenic process. In addition, it appears that PB both inhibits apoptosis and enhances DNA synthesis in hepatic lesions in both mice and rats. Furthermore, in both species, PB preferentially affected the growth of eosinophilic lesions. Previous studies have indicated that PB treatment in rats exhibits a threshold response in hepatic tumor promotion and carcinogenicity (13, 32, 33) . In F344 rats, a single injection of 2-acetylaminofluorene followed by chronic PB administration resulted in an increase in the multiplicity and incidence of hepatic tumors at a dietary dose of 100 mg/kg (34) . A dietary concentration of 20 mg/kg PB resulted in a significant increase in only the number but not the incidence of hepatic neoplasms (24) . In Fisher 344 rats treated with 100 mg/kg DEN followed by PB promotion, no significant increase in the number of focal lesions after treatment of PB doses of 1, 4, 16 or 75 mg/ ml (13) . Concentrations of 300 and 1200 mg PB/ml were effective in the promotion of hepatic cancer (13) . DEN treatment (80 mg/kg gavage) followed by 70 weeks of PB dietary feeding in Sprague-Dawley rats did not increase the incidence of hepatocellular cancer at doses of 62.5 and 125 mg/kg (12) . A significant increase in hepatic tumors at PB concentrations of 250, 500 and 1000 mg/kg diet was seen in this study (12) . After 3'-Me-DAB treatment, rats fed PB for 12 weeks exhibited significant increases in the number of focal lesions at PB concentrations of 100 and 500 mg/kg but not at concentrations of 50 or 20 mg/kg. After 24 weeks, however, 952 there was no observable threshold, as rats treated with 20, 50, 100 and 500 mg PB/kg diet had significantly elevated numbers of preneoplastic lesions (35) . F344 rats initiated by DEN followed by partial hepatectomy and then fed PB for 7-8 months had significantly greater number of preneoplastic lesions at doses of 50, 100, 500, 1500 and 2000 mg/kg diet (11, 36) . There was no significant change in the number of lesions per liver in rats fed PB at concentrations of 1 or 10 mg/kg diet (11) . In the present study, a PB concentration of 10 mg/kg diet did not promote the growth of focal lesions in mice or rats. This observation correlates with similar findings of a threshold promotion dose of PB in rats reported by Goldsworthy et al. (11) .
The different methods used to initiate rodents may influence the dose dependent ability of PB to promote DEN-initiated hepatic lesions. In B6C3F1 male mice, the time and dose at which DEN is administered appears critical to the ability of PB to promote preneoplastic growth. Fifteen day old mice injected with DEN followed by chronic PB treatment showed a decreased number of hepatocellular neoplasms (25) . In addition, treatment of B6C3F1 mice with 80 mg DEN/kg body weight followed by PB promotion does not result in an increased number of hepatocellular lesions until 168 days of treatment, while similarly initiated mice treated with di(2-ethyl)-hexylphthalate (DEHP) have significant increases after 28 days of exposure (23) . Thirty day old B6C3F1 male mice initiated with DEN are susceptible to PB induction of preneoplastic and neoplastic lesions (25) .
Different classes of preneoplastic focal lesions may possess differential sensitivities to promoting chemicals, e.g. PB treatment following DEN initiation has been shown to increase preferentially the number of eosinophilic focal lesions (22) (23) (24) . The data herein indicate that PB treatment increases the number and volume of eosinophilic lesions in both mice and rats. Our data also show that treatment with PB preferentially modulated apoptosis and DNA synthesis in eosinophilic lesions in both mice and rats. Previous studies have shown that PB treatment in DEN-initiated mice resulted in increased numbers of eosinophilic focal lesions and adenomas (19, 25) . The relevance of this preferential promoting effect of PB on eosinophilic focal lesions to the overall hepatocarcinogenic effect of PB is unclear, pending definitive evidence that eosinophilic focal lesions are precursors to hepatic neoplasms induced by PB.
Non-genotoxic hepatocarcinogens have been proposed to function via a variety of different mechanisms. An increase in DNA synthesis in naive (normal, non-initiated) liver has been speculated to lead to an increased probability of formation of an initiated cell through a perturbation of DNA base pairing (37) . Previously, we have shown that there was only a transient increase in DNA synthesis in the naive liver in mice and rats following subchronic PB administration (38) . In addition, there was no increase in DNA synthesis in either species treated with 10 mg PB/kg diet (38) . While the normal hepatocytes exhibited a brief induction of DNA synthesis following 500 mg PB/kg treatment, data in this paper indicate that DNA synthesis in hepatic focal lesions in mice and rats exposed to 500 mg PB/kg diet was persistently elevated throughout PB treatment. Increased DNA synthesis in preneoplastic hepatocytes increases cell number (39) , and may be responsible for the formation of hepatocellular cancer induced by non-genotoxic carcinogens (1, (4) (5) (6) 37, 40) . Work by this laboratory and others have shown that treatment with non-genotoxic hepatocarcinogens significantly elevates DNA synthesis in focal lesions when compared to untreated control preneoplastic lesions, possibly giving promoter-treated lesions a selective growth advantage (4, 15) .
Studies by Schulte-Hermann and co-workers have indicated that the growth of preneoplastic lesions induced by nongenotoxic hepatocarcinogens is predominantly attributed to an inhibition of programmed cell death/apoptosis (18). Apoptosis is a morphological description of an active process that results in selective cell death without an induction of the immune response (41, 42) . The occurrence of this process is rare in normal liver, but the relative rate appears to increase in focal lesions (18, 30) . In this study, we observed an inhibition of apoptosis in preneoplastic lesions in mice and rats initiated with DEN followed by treatment with PB. This PB-induced inhibition of apoptosis was observed solely in eosinophilic lesions (doses of 100 and 500 mg PB/kg diet). A recent paper investigating TCDD promotion in DEN-initiated F344 rats indicated that treatment with TCDD inhibited apoptosis while increasing DNA synthesis in focal hepatic lesions (21) . A similar response following PB treatment is reported herein. Inhibition of apoptosis accompanied by increased focal DNA synthesis leads to the enhancement of preneoplastic lesion growth. The combination of these two processes together effectively increase the number and volume of preneoplastic lesions, and appear to specifically target eosinophilic lesions. The increased number of focal lesions may be attributed to either an increased growth of lesions that were previously histologically unevident (43) , or an increase in the size of existing lesions, resulting in a greater probability of being sectioned (44) .
In addition to the above data, the study of focal lesion growth serves as a model to research the mechanism of action of non-genotoxic hepatocarcinogens and to define risk assessment via dose-response characteristics of tumor promotion. Overall, in mice and rats, the growth response seen in focal lesions occurred at doses of 100 and 500 mg PB/kg diet that had previously been shown to exhibit tumor-promoting and carcinogenic activity in rodents (11) (12) (13) . The data presented herein suggest that in both mice and rats, suprathreshold concentrations of PB cause initiated cells and preneoplastic lesions to expand clonally via inhibition of apoptosis and stimulation of DNA synthesis.
